MedTrace Logo

Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.

NCT04082806 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2022-05-12

No results posted yet for this study

Summary

30 healthy adults and 30 patients with major depressive disorder, will take part in three single-application pharmacological interventions (GHB vs. Trazodone vs. placebo p.o.) to test potential effects of these drugs on nocturnal memory consolidation. All participants will be assessed with mood state questionnaires, tests of emotional, procedural and declarative memory consolidation, polysomnography, EEG and neuroinflammatory biomarkers. At experimental nights, learning tasks are performed prior to sleep. The next morning, recalling tasks are performed. Each subject will pass through 5 study nights (1 screening, 1 adaptation and 3 experimental nights).

Conditions

Interventions

DRUG

GHB

50 mg/kg GHB at one experimental night

DRUG

Trazodone

1.5 mg/kg trazodone at one experimental night

DRUG

Placebos

placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)

Sponsors & Collaborators

  • Erich Seifritz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2022-04-06
Completion
2022-04-06

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04082806 on ClinicalTrials.gov